

[illegible]



CRC / TRR 241 Newsletter

Issue 14 - July 2025

Important information „TRR241 Time line full proposal“

Relevant for	Deadline	Task
Full proposal	15 th July 2025	Please upload: • <i>“List of existing instruments_PROJECT ID”</i> • <i>“Other third party funding__PROJECT ID”</i>
Full proposal	01 th September 2025	Please upload: • <i>“Project ID_version 1” +</i> • <i>“10 lines main achievements_PROJECT ID”</i> • <i>“5 lines project summary_PROJECT ID”</i> • <i>if applicable: updates of CV, tables etc.</i>
Full proposal	15 th September 2025	Please upload: • <i>“Data Management_PROJECT ID”</i> • <i>“Imaging_PROJECT ID”</i>
Full proposal	09 th - 10 th October 2025	Meeting in person (PIs only) in Erlangen
Full proposal	17 th October 2025	Please upload: • <i>“Project ID_version 2”</i> • <i>final updates of CV, tables etc.</i>
Full proposal	14 th November 2025	Please upload: • <i>“Project ID_final version”</i>
Full proposal	24 th November 2025	Print of full proposal
Full proposal	01 st December 2025	Sending the final proposal and research profiles to the DFG Head Office
Full proposal	04 th December 2025	Deadline DFG
Onsite Review Berlin	13 th January 2026	Rehearsal I - online
Onsite Review Berlin	20 th January 2026	Rehearsal II - Erlangen
Onsite Review Berlin	28 th January 2026	Rehearsal III - Berlin
Onsite Review Berlin	29 th January 2026	TRR241 + DFG
Onsite Review Berlin	30 th January 2026	Review Board, Speakers, University management and If necessary, individual PIs for inquiries



CRC / TRR 241 Newsletter

Issue 14 - July 2025

New CRC TRR 241 publications (2024)

Neurath MF, Berg LJ. VAV1 as a putative therapeutic target in autoimmune and chronic inflammatory diseases. Trends Immunol. 2024 Aug;45(8):580-596. doi: 10.1016/j.it.2024.06.004.

Röwekamp I, Maschirow L, Rabes A, Fiocca Vernengo F, Hamann L, Heinz GA, Mashreghi MF, Caesar S, Milek M, Fagundes Fonseca AC, Wienhold SM, Nouailles G, Yao L, Mousavi S, Bruder D, Boehme JD, Puzianowska-Kuznicka M, Beule D, Witzenrath M; CAPNETZ Study Group; Löhning M, **Klose CSN**, Heimesaat MM, **Diefenbach A**, Opitz B. IL-33 controls IL-22-dependent antibacterial defense by modulating the microbiota. Proc Natl Acad Sci U S A. 2024 May 28;121(22):e2310864121. doi: 10.1073/pnas.2310864121.

Jacobsen A, Siebler J, Grützmann R, **Stürzl M**, Naschberger E. Blood Vessel-Targeted Therapy in Colorectal Cancer: Current Strategies and Future Perspectives. Cancers (Basel). 2024 Feb 22;16(5):890. doi: 10.3390/cancers16050890.

Essex M, Rios Rodriguez V, Rademacher J, Proft F, Löber U, Markó L, Pleyer U, Strowig T, Marchand J, Kirwan JA, **Siegmund B**, Forslund SK, Poddubnyy D. Shared and Distinct Gut Microbiota in Spondyloarthritis, Acute Anterior Uveitis, and Crohn's Disease. Arthritis Rheumatol. 2024 Jan;76(1):48-58. doi: 10.1002/art.42658.

Gámez-Belmonte R, Wagner Y, Mahapatro M, Wang R, Erkert L, González-Acera M, Cineus R, Hainbuch S, **Patankar JV**, Voehringer D, **Hegazy AN**, **Neurath MF**, **Wirtz S**, **Becker C**. Intestinal epithelial Gasdermin C is induced by IL-4R/STAT6 signaling but is dispensable for gut immune homeostasis. Sci Rep. 2024 Nov 3;14(1):26522. doi: 10.1038/s41598-024-78336-z.

Atreya R, Rath T, **Neurath MF**. Molecular Imaging: The New Frontier for Endoscopic Diagnosis and Personalization in Inflammatory Bowel Disease. Gastrointest Endosc Clin N Am. 2025 Jan;35(1):255-263. doi: 10.1016/j.giec.2024.09.002.

Almalla A, Alzain N, Elomaa L, Richter F, Scholz J, Lindner M, **Siegmund B**, Weinhart M. Hydrogel-Integrated Millifluidic Systems: Advancing the Fabrication of Mucus-Producing Human Intestinal Models. Cells. 2024 Jun 21;13(13):1080. doi: 10.3390/cells13131080.

Beck M, Kuwert T, Atzinger A, Gerner M, Hartmann A, Saake M, Uder M, **Neurath MF**, **Atreya R**. Discrimination between Inflammatory and Fibrotic Activity in Crohn's Disease-Associated Ileal-Colonic Anastomotic Strictures by Combined Ga-68-FAPI-46 and F-18-FDG-PET/CT Imaging. Visc Med. 2025 Feb;41(1):1-13. doi: 10.1159/000542160.

Fischer S, Donhauser M, Cohnen S, Fietkau K, Vetter M, Grübel-Liehr M, Dietrich P, Rath T, Wilfer A, Sologub L, Krebs S, Dörje F, Nagore D, Meyer S, **Neurath MF**, **Atreya R**. Reverse switching from the biosimilar SB2 to the originator infliximab in previously switched patients with inflammatory bowel diseases: results of a prospective long-term cohort study. Therap Adv Gastroenterol. 2024 Nov 30;17:17562848241301887. doi: 10.1177/17562848241301887.



CRC / TRR 241 Newsletter

Issue 14 - July 2025

New CRC TRR 241 publications (2025/1)

Plechs Schmidt J, Fietkau K, Hepp T, Dietrich P, Fischer S, Krebs S, **Neurath MF**, Dörje F, **Atreya R**. Clinical Pharmacist Counselling Improves Long-term Medication Safety and Patient-reported Outcomes in Anti-TNF-treated Patients With Inflammatory Bowel Diseases: The Prospective, Randomized AdPhaNCED Trial. *Inflamm Bowel Dis*. 2025 Jan 6;31(1):77-86. doi: 10.1093/ibd/izae040.

Stallmach A, Stallhofer J, Schmidt C, **Atreya R**, Grunert PC. Therapie des schweren Schubs bei Morbus Crohn und Colitis ulcerosa [Treatment of severe flares in Crohn's disease and ulcerative colitis]. *Inn Med (Heidelb)*. 2025 Jan;66(1):22-30. German. doi: 10.1007/s00108-024-01825-w.

Atreya R, Rath T, **Neurath MF**. Molecular Imaging: The New Frontier for Endoscopic Diagnosis and Personalization in Inflammatory Bowel Disease. *Gastrointest Endosc Clin N Am*. 2025 Jan;35(1):255-263. doi: 10.1016/j.giec.2024.09.002.

Bao LL, Yu YQ, González-Acera M, **Patankar JV**, Giessl A, Sturm G, **Kühl AA**, **Atreya R**, Erkert L, Gámez-Belmonte R, Krug SM, Schmid B, Tripal P, Chiriac MT, **Hildner K**, **Siegmund B**, **Wirtz S**, **Stürzl M**, Mohamed Abdou M, **Trajanoski Z**; **TRR241 IBDome Consortium**; **Neurath MF**, Zorzano A, **Becker C**. Epithelial OPA1 links mitochondrial fusion to inflammatory bowel disease. *Sci Transl Med*. 2025 Jan 15;17(781):eadn8699. doi: 10.1126/scitranslmed.adn8699.

Müller TM, Liu LJ, Wiesinger M; **TRR241 IBDome Consortium**; **Neurath MF**, **Voskens CJ**, **Zundler S**. Engineering Therapeutic Regulatory T Cells to Overexpress G Protein-Coupled Receptor 15 Improves Functional Fitness for In Vivo Gut Homing. *Gastroenterology*. 2025 Feb;168(2):389-392.e4. doi: 10.1053/j.gastro.2024.10.003.

Roth D, Düll MM, Horst LJ, Lindemann A, Malzer X, **Koop K**, **Zundler S**, Vetter M, Jefremow A, **Atreya R**, Geppert C, Weidemann S, **Waldner MJ**, Dietrich P, **Günther C**, Munoz LE, Herrmann M, **Scheffold A**, **Neurath MF**, Siebler J, Schramm C, Kremer AE, **Leppkes M**. Integrin $\alpha V\beta 6$: Autoantigen and Driver of Epithelial Remodeling in Colon and Bile Ducts in Primary Sclerosing Cholangitis and Inflammatory Bowel Disease. *J Crohns Colitis*. 2025 Feb 4;19(2):jjae131. doi: 10.1093/ecco-jcc/jjae131.

Horn V, Cancino CA, Steinheuer LM, Obermayer B, Fritz K, Nguyen AL, Juhran KS, Plattner C, Bösel D, Oldenburg L, Burns M, Schulz AR, Saliutina M, Mantzivi E, Lissner D, Conrad T, Mashreghi MF, **Zundler S**, Sonnenberg E, **Schumann M**, Haag LM, Beule D, Flatz L; **TRR241 IBDome Consortium**; **Trajanoski Z**, D'Haens G, **Weidinger C**, Mei HE, **Siegmund B**, Thurley K, **Hegazy AN**. Multimodal Profiling of Peripheral Blood Identifies Proliferating Circulating Effector CD4⁺ T Cells as Predictors for Response to Integrin $\alpha 4\beta 7$ -Blocking Therapy in Inflammatory Bowel Disease. *Gastroenterology*. 2025 Feb;168(2):327-343. doi: 10.1053/j.gastro.2024.09.021.

Beck M, Kuwert T, Atzinger A, Gerner M, Hartmann A, Saake M, Uder M, **Neurath MF**, **Atreya R**. Discrimination between Inflammatory and Fibrotic Activity in Crohn's Disease-Associated Ileal-Colonic Anastomotic Strictures by Combined Ga-68-FAPI-46 and F-18-FDG-PET/CT Imaging. *Visc Med*. 2025 Feb;41(1):1-13. doi: 10.1159/000542160.

Atreya R, **Neurath MF**. No easy way out: blocking lymphocyte egress by the S1P1 receptor 1 modulator tamuzimod in ulcerative colitis. *Lancet Gastroenterol Hepatol*. 2025 Mar;10(3):185-187. doi: 10.1016/S2468-1253(24)00397-2.



CRC / TRR 241 Newsletter

Issue 14 - July 2025

New CRC TRR 241 publications (2025/1)

Feng X, Andersson T, Flüchter P, Gschwend J, Berest I, Muff JL, Lechner A, Gondrand A, Westermann P, Brander N, Carchidi D, De Tenorio JC, Pan T, Boehm U, **Klose CSN**, Artis D, Messner CB, Leinders-Zufall T, Zufall F, Schneider C. Tuft cell IL-17RB restrains IL-25 bioavailability and reveals context-dependent ILC2 hypoproliferation. *Nat Immunol*. 2025 Apr;26(4):567-581. doi: 10.1038/s41590-025-02104-y.

Gonzalez-Acera M, **Patankar JV**, Erkert L, Cineus R, Gamez-Belmonte R, Leupold T, Bubeck M, Bao LL, Dinkel M, Wang R, Schickedanz L, Limberger H, Stolzer I, Gerlach K, Diemand L, Mascia F, Gupta P, Naschberger E, **Koop K**, Plattner C, Sturm G, Weigmann B, **Günther C**, **Wirtz S**, **Stürzl M**, **Hildner K**, **Kühl AA**, **Siegmund B**, Gießl A, **Atreya R**; **TRR241 IBDome Consortium**; **Hegazy AN**, **Trajanoski Z**, **Neurath MF**, **Becker C**. Integrated multimodel analysis of intestinal inflammation exposes key molecular features of preclinical and clinical IBD. *Gut*. 2025 Apr 29;gutjnl-2024-333729. doi: 10.1136/gutjnl-2024-333729.

Plattner C, Sturm G, **Kühl AA**, **Atreya R**, Carollo S, Gronauer R, Rieder D, Günther M, Ormanns S, Manzl C, **Wirtz S**, Meneghetti AR, **Hegazy AN**, **Patankar JV**, Carrero ZI; **TRR241 IBDome Consortium**; **Neurath MF**, Kather JN, **Becker C**, **Siegmund B**, **Trajanoski Z**. IBDome: An integrated molecular, histopathological, and clinical atlas of inflammatory bowel diseases. *bioRxiv [Preprint]*. 2025 Apr 10:2025.03.26.645544. doi: 10.1101/2025.03.26.645544.

Erkert L, Ruder B, Kabisch M, Gamez Belmonte R, **Patankar JV**, Gonzalez Acera M, Schödel L, Chiriac MT, Cineus R, Gnafakis S, Leupold T, Thoma OM, Stolzer I, Taut A, Thonn V, **Zundler S**, **Günther C**, **Diefenbach A**, **Kühl AA**, **Hegazy AN**, **Waldner M**, Basic M, Bleich A, **Neurath MF**, **Wirtz S**, **Becker C**; **TRR241 IBDome Consortium**. TIFA renders intestinal epithelial cells responsive to microbial ADP-heptose and drives colonic inflammation in mice. *Mucosal Immunol*. 2025 Apr;18(2):453-466. doi: 10.1016/j.mucimm.2025.01.003.

Hecker J, Plattner C, Cancino CA, Löscher BS, Saurenbach J, Letizia M, Rieder D; **TRR241 IBDome Consortium**; Freise I, **Koop K**, **Neufert C**, Kunkel D, Al Khatim Z, Schaafs LA, Schütz A, **Becker C**, **Atreya R**, **Trajanoski Z**, Franke A, Sonnenberg E, **Hegazy AN**, **Siegmund B**, **Weidinger C**. IL-36 signaling as a drug target in Crohn's disease patients with IL36RN mutations. *EMBO Mol Med*. 2025 May 30. doi: 10.1038/s44321-025-00245-z.

Avery EG, Haag LM, McParland V, Kedziora SM, Zigra GJ, Valdes DS, Kirchner M, Popp O, Geisberger S, Nonn O, Karlsen TV, N'Diaye G, Yarritu A, Bartolomaeus H, Bartolomaeus TUP, Tagiyeva NA, Wimmer MI, Haase N, Zhang YD, Wilhelm A, Grütz G, Tenstad O, Wilck N, Forslund SK, Klopffleisch R, **Kühl AA**, **Atreya R**, Kempa S, Mertins P, **Siegmund B**, Wiig H, Müller DN. Intestinal interstitial fluid isolation provides novel insight into the human host-microbiome interface. *Cardiovasc Res*. 2025 May 23;121(5):803-816. doi: 10.1093/cvr/cvae267.

Forster PM, Jakob MO, Yusuf D, Bubeck M, Limberger H, Luo Y, Thieme P, Polici A, Sterczyk N, Boulekou S, Bartel L, Cosovanu C, Witkowski M, González-Acera M, **Kühl AA**, **Weidinger C**; **TRR241 IBDome Consortium**; Backofen R, **Hegazy AN**, **Patankar JV**, **Klose CSN**. A transcriptional atlas of gut-innervating neurons reveals activation of interferon signaling and ferroptosis during intestinal inflammation. *Neuron*. 2025 May 7;113(9):1333-1351.e7. doi: 10.1016/j.neuron.2025.02.018.



CRC / TRR 241 Newsletter

Issue 14 - July 2025

New CRC TRR 241 publications (2025/1)

Lehmann M, Paclik D, Huck A, Arnold A, Kurth-Stavenhagen C, Vieth M, Treese C, **Kühl AA**, **Siegmund B**. Spatial immune profiling of Crohn's disease fistula carcinomas-defining a distinct cancer subtype. J Crohns Colitis. 2025 Jun 4;19(6):jjaf086. doi: 10.1093/ecco-jcc/jjaf086.

Cineus R, Luo Y, Saliutina M, Manna S, Cancino CA, Velasco Blázquez L, Wang L, Bösel D, Abdelrahman A, Klementowicz JE, Scherl A, Hainbuch S, Bréart B, Kwon G, Konopka A, Guerra GM, von Coburg E, Gerbeth L, Roels J, Heinrich F, Müller N, Durek P, Deigendes N, Ziai J, Hung J, Conrad T; **TRR241 IBDome Consortium**; **Kühl AA**, **Wirtz S**, Löhning M, Keir M, **Diefenbach A**, Mashreghi MF, **Siegmund B**, **Schumann M**, **Romagnani C**, West NR, **Hegazy AN**. The IL-22-oncostatin M axis promotes intestinal inflammation and tumorigenesis. Nat Immunol. 2025 Jun;26(6):837-853. doi: 10.1038/s41590-025-02149-z.

Neurath MF, Artis D, **Becker C**. The intestinal barrier: a pivotal role in health, inflammation, and cancer. Lancet Gastroenterol Hepatol. 2025 Jun;10(6):573-592. doi: 10.1016/S2468-1253(24)00390-X.

Atreya R, **Neurath MF**. MRI Volumetric Changes in Perianal Fistulizing Crohn's Disease: Moving Toward a Novel Outcome Measure for Therapeutic Response. United European Gastroenterol J. 2025 Jun;13(5):667-668. doi: 10.1002/ueg2.12765.

Liu LJ, Müller TM, Dedden M, Schramm S, **Leppkes M**, **Atreya R**, **Atreya I**; **TRR241 IBDome consortium**; **Neurath MF**, **Zundler S**. ST6GAL1 promotes IBD B cell recruitment to the inflamed colon in a CD22-dependent mechanism. J Crohns Colitis. 2025 Jun 10;jjaf097. doi: 10.1093/ecco-jcc/jjaf097.

Erkert L, Kabisch M, Gamez-Belmonte R, Gonzalez-Acera M, **Patankar JV**, Schödel L, Hofmann K, Wagner Y, Plattner C, Spath EM, Distler U, Tenzer S; **TRR241 IBDome Consortium**; **Neufert C**, **Neurath MF**, **Becker C**. Pharmacological inhibitors of the gamma-secretase enzyme complex disrupt epithelial cell function triggering colitis in mice. J Crohns Colitis. 2025 Jun 12;jjaf096. doi: 10.1093/ecco-jcc/jjaf096.

Masanetz RK, Mundlos H, Stolzer I, Winkler J, **Günther C**, Süß P. Absence of Microglial Activation and Maintained Hippocampal Neurogenesis in a Transgenic Mouse Model of Crohn's Disease. Cells. 2025 Jun 4;14(11):841. doi: 10.3390/cells14110841.